A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Trial Profile

A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Valproic acid (Primary)
  • Indications Sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Feb 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 10 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 Jun 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top